C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2026)

C4 Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 27446000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 4.27% year-over-year to 27446000.0 in Q1 2026; TTM through Mar 2026 was 105997000.0, a 2.63% decrease from a year earlier, with the FY2025 full-year figure at 104994000.0, changed 0.31% from the prior year.
• Income from Continuing Operations eased to 27446000.0 in Q1 2026 per CCCC's latest filing, from 20365000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 17716000.0 in Q2 2024 and bottomed at 128670000.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 31620000.0 (2022), against an average of 35268470.59.
• Across the five-year window, Income from Continuing Operations plunged 469.84% in 2022 and jumped 72.08% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 37185000.0 in 2022, then increased by 6.53% to 34757000.0 in 2023, then increased by 0.53% to 34573000.0 in 2024, then soared by 41.1% to 20365000.0 in 2025, then slumped by 34.77% to 27446000.0 in 2026.
• Per Business Quant, the three latest CCCC Income from Continuing Operations figures stand at 27446000.0 (Q1 2026), 20365000.0 (Q4 2025), and 32166000.0 (Q3 2025).